A study evaluating T-DM1 in combination with docetaxel (with or without pertuzumab) for HER2-positive breast cancer demonstrated that the objective response rate (ORR) of combination therapy was 47.8%, with a median PFS of 7.4 months. The gene discussed is ERBB2; the disease is breast carcinoma.